1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Acute Spinal Cord Injury - Pipeline Review, H2 2015

Acute Spinal Cord Injury - Pipeline Review, H2 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 52 pages

Acute Spinal Cord Injury - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Spinal Cord Injury - Pipeline Review, H2 2015’, provides an overview of the Acute Spinal Cord Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Spinal Cord Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Spinal Cord Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acute Spinal Cord Injury - Pipeline Review, H2 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Spinal Cord Injury Overview 6
Therapeutics Development 7
Pipeline Products for Acute Spinal Cord Injury - Overview 7
Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis 8
Acute Spinal Cord Injury - Therapeutics under Development by Companies 9
Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 10
Acute Spinal Cord Injury - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Acute Spinal Cord Injury - Products under Development by Companies 13
Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes 14
Acute Spinal Cord Injury - Companies Involved in Therapeutics Development 15
Kringle Pharma, Inc. 15
Neuralstem, Inc. 16
Neuronax SAS 17
Vertex Pharmaceuticals Incorporated 18
Acute Spinal Cord Injury - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Cell Therapy for Spinal Cord Injury - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
KP-100IT - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
NSI-566 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
NX-210 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
VX-210 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Acute Spinal Cord Injury - Recent Pipeline Updates 40
Acute Spinal Cord Injury - Dormant Projects 48
Acute Spinal Cord Injury - Discontinued Products 49
Acute Spinal Cord Injury - Product Development Milestones 50
Featured News and Press Releases 50
Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries 50
Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables
Number of Products under Development for Acute Spinal Cord Injury, H2 2015 7
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015 15
Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015 16
Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015 17
Acute Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015 40
Acute Spinal Cord Injury - Dormant Projects, H2 2015 48
Acute Spinal Cord Injury - Discontinued Products, H2 2015 49

List of Figures
Number of Products under Development for Acute Spinal Cord Injury, H2 2015 7
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 20
Number of Products by Stage and Top 10 Targets, H2 2015 20
Number of Products by Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24
Number of Products by Top 10 Molecule Types, H2 2015 26
Number of Products by Stage and Top 10 Molecule Types, H2 2015 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.